Key Findings
A total of 1,660 patients completed the 52-week treatment phase across both groups (830 patients in each arm). Analysis revealed statistically significant and clinically meaningful improvements with dupilumab compared to placebo in both HRQoL and respiratory symptom severity measures.
– SGRQ Total Score: Dupilumab lowered the mean total score by a least squares mean difference of -3.4 (95% CI: -5.0 to -1.8; P < .0001) relative to placebo, denoting improved quality of life.
